Description du projet
Un médicament contre la sclérose en plaques pour traiter l’insuffisance cardiaque
Les maladies cardiovasculaires sont la principale cause de décès dans les pays développés, avec des millions de cas rien qu’en Europe. Elles sont liées à une diminution du flux sanguin vers le cœur, ce qui peut entraîner des crises cardiaques. Dans l’optique de réparer le muscle cardiaque, qui est le problème clé après une crise cardiaque, le projet ReDHeaD, financé par l’UE, testera le Copaxone, un médicament approuvé par la FDA qui est utilisé dans le traitement de la sclérose en plaques. Des données précliniques montrent une amélioration significative des paramètres de la fonction cardiaque après l’administration de Copaxone. Les chercheurs prépareront des essais cliniques pour valider l’efficacité du médicament chez l’homme et entreprendront toutes les démarches de réglementation et de commercialisation nécessaires pour sa traduction clinique rapide.
Objectif
Coronary Heart Disease (CHD) and particularly Myocardial Infarction (MI), i.e. heart attack, is the leading cause of death in the Western world today. The main cause for CHD is the incapacity of the mammalian heart to undergo regeneration after injury. Current therapies are not able to address the central problem of decreased pumping capacity that results from the depleted pool of cardiac muscle cells. The outcome of this shortcoming is grim; nearly half of all patients with heart failure die within five years of the initial diagnosis.
We have tested a widely used FDA approved drug, Copaxone, which is used to treat Multiple Sclerosis, for its efficacy in heart repair and made a breakthrough discovery. Copaxone improved cardiac function and reduced scarring in a mouse MI model. Most of the treated mice (85%) responded to the treatment, exhibiting an average improvement of 44% in heart function parameters, along with 40% reduction in scar size.
In this PoC, we will expand these experiments by testing Copaxone using a chronic heart failure (CHF) model in both small and large animals (rats, pigs), and determine the optimal dosage regimen. Based on positive findings in this PoC, we plan to pursue Phase II clinical trials. The suggested activities include the preparation of the commercialization by interacting with key opinion leaders (e.g. cardiologists), who are in the position to speed up the clinical translation. We will also interact with pharma companies to build a potential collaborator and customer network. Eventually, we aim at commercializing repurposing existing drug to treat heart diseases, for CHF or acute MI indications. The impact of such therapy would be vast: CHD is the most common cause of death in Europe, accounting for 1.8 million deaths each year. As the original drug was already successfully commercialized by our institute, we can build on this experience and have the treatment available in approximately 5-6 years.
Champ scientifique
Programme(s)
Régime de financement
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotInstitution d’accueil
7610001 Rehovot
Israël